BIOGEN, INC. (NASDAQ:BIIB)
188.38 USD 
-0.21 (-0.11%)
Delayed Price / Updated:
4:00 PM EDT, Oct 11, 2024 / Add to My Watchlist
Company Information
Financial Snapshot
| Annual | 12/2023FY | 12/2024FY |
|---|---|---|
| Total Revenue | $9.43 B | $9.42 B |
| Net Income | $3.05 B | $1.16 B |
| Quarterly | 12/31/2023 | 3/31/2024 |
| Total Assets | $26.84 B | $26.57 B |
| Total Liabilities | $11.35 B | $10.92 B |
| Operating Margin | 18.49% | 24.79% |
Address and Details
| Biogen, Inc.
225 Binney Street |
|
| Industry | Pharmaceuticals: Major |
|---|---|
| Sector | Health Technology |
| Employees | 7,570 |
Business Summary
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Company Officers
| Mr. Christopher A. Viehbacher | Mr. Christopher A. Viehbacher | Mr. Michael R. McDonnell | |||||||||||||||||||||||
| President, Chief Executive Officer & Director | President, Chief Executive Officer & Director | Chief Financial Officer & Executive Vice President | |||||||||||||||||||||||
| Mr. Michael E. Dambach | Ms. Robin C. Kramer | Dr. Jane Grogan | Ms. Nicole Murphy | Ms. Nicole Murphy | Dr. Eric K. Rowinsky | Dr. Eric K. Rowinsky | Dr. Stephen A. Sherwin | Dr. Stephen A. Sherwin | Mr. Monish Patolawala | Mr. Monish Patolawala | Mr. Christopher A. Viehbacher | Ms. Susan Langer | Mr. William A. Hawkins | Mr. Jesus B. Mantas | Mr. Jesus B. Mantas | Dr. Maria C. Freire | Dr. Maria C. Freire | Ms. Caroline D. Dorsa | Ms. Caroline D. Dorsa | Mr. William A. Hawkins | Dr. Lloyd B. Minor | Dr. Menelas NICOLAS Pangalos | Ms. Susan Langer | Mr. Wendell C. Taylor | |
| Treasurer & Vice President | Chief Accounting Officer & Senior Vice President | Executive Vice President & Head-Research | Head-Pharmaceutical Operations & Technology | Head-Pharmaceutical Operations & Technology | Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | President, Chief Executive Officer & Director | Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | Chairman | Chairman | Independent Director | Director | Director | Independent Director | Secretary & Chief Counsel |
Revenue, Returns and Ratios
Total Revenue - TTM
;Total|Revenue(Prev%20Qtr)&BAR_VALUE_SUFFIX=B&YAXIS_LABEL_SUFFIX=B&BAR_WIDTH=90&BAR_VALUE_PREFIX=$&YAXIS_LABEL_PREFIX=$)
Ratios
;P/E|Ratio%20(FY);Debt/Equity|Ratio%20(MRQ)&BAR_VALUE_SUFFIX=&YAXIS_LABEL_SUFFIX=&BAR_WIDTH=55&YSEPLINES=2)
Revenue Summary - TTM
Return on Equity vs. Return on Assets
;Return%20on|Assests%20(MRQ)&BAR_VALUE_SUFFIX=%25&YAXIS_LABEL_SUFFIX=%25&BAR_WIDTH=90)
Per Share
;Cash%20Flow%20Per|Share%20(FY)&BAR_VALUE_SUFFIX=&YAXIS_LABEL_SUFFIX=&BAR_WIDTH=55&YSEPLINES=2)
Peer Comparison
| Company Name | Price | EPS (FY) | Annual Dividend | Book Value (FY) | Cash Flow (FY) |
|---|---|---|---|---|---|
| Biogen, Inc. | $188.38 | 7.97 | 0.00 | 109.05 | 17.40 |